Articles tagged with Cancer Patients
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for anal cancer, providing guidance on treatment options and techniques. The guideline recommends a combination of radiation therapy and drug therapy as the standard of care, with intensity-modulated radiation therapy (IM...
Researchers found that training the innate immune system can exacerbate inflammatory bone loss in models of chronic diseases like periodontitis and arthritis. The study suggests that a previously thought beneficial effect of trained immunity may actually contribute to harm in certain contexts.
Researchers have developed a new strategy to protect cancer patients from radiation-induced DNA damage using a protein from tardigrades. The approach makes use of messenger RNA encoding the protein, which is delivered to patient tissues before radiation treatment. This reduces double-stranded DNA breaks by 50% in mouse models.
Researchers at MD Anderson Cancer Center have identified biomarkers for predicting treatment response in metastatic breast cancer and found a potential target for tumor progression in pancreatic cancer. Additionally, they discovered that abnormal chromosome changes predict survival in patients with secondary acute myeloid leukemia.
A study published in Plastic and Reconstructive Surgery reports that women who undergo breast-conserving therapy (BCT) experience improved sexual well-being compared to those who receive post-mastectomy breast reconstruction (PMBR). Scores on a sexual well-being subscale were consistently higher for BCT patients, with average scores 7....
Increased visceral adipose tissue density and decreased skeletal muscle area are predictors of post-esophagectomy pulmonary complications. Decreased skeletal muscle density is associated with poorer overall survival. Routine morphomic analysis can help identify patients at risk and tailor perioperative care.
A recent study published in CANCER suggests that higher levels of physical activity may lessen and even eliminate survival disparities among colon cancer survivors. Cancer survivors who regularly exercised achieved better subsequent survival rates than those seen in the matched general population, with a 3.1% lower risk at year three.
New research reveals aldosterone-producing adenomas harbor at least four distinct cell types, including cortisol-producing cells that contribute to unexpected health issues. The study also identifies potential role of lipid-associated macrophages in influencing hormone production and tumor growth.
A study of 33,744 Medicare decedents found that 45% received potentially aggressive care in the last days of life, while only 25% received advanced care planning and palliative care. Despite efforts to raise awareness about the harms of aggressive treatment, access to supportive care varies among demographic groups.
A retrospective study found that only one-quarter of patients diagnosed with advanced cancer received palliative care in the last six months of life. The study also showed that 45% of decedents experienced potentially aggressive care, highlighting the need for interventions to improve quality of care.
A recent study has identified that the neuronal subtype responds best to immunotherapy, while other subtypes exhibit lower response rates. The researchers developed a machine-learning algorithm using large public data sets to predict treatment response based on tumor mutational burden and immune cell infiltration.
A recent Lancet article revealed that durvalumab combined with radiation therapy offers no benefits for patients with head and neck cancer who cannot receive cisplatin. However, a new clinical trial is underway to test the use of a heavy metal to enhance radiation therapy, providing potential new options for these patients.
A rare case of adenomyosis in an 81-year-old postmenopausal woman closely resembles invasive endometrial cancer, emphasizing the challenges of diagnosing this condition. Further studies are needed to refine diagnostic protocols and determine risk factors for postmenopausal patients.
A pilot study shows that a text messaging system can safely reduce the amount of time some patients spend receiving cancer treatment. The platform, which was tested in a clinical trial, allowed patients to complete symptom checks and receive approval for fast-tracking their treatments, saving them over an hour per visit.
The joint venture aims to build the world's preeminent pediatric cancer center, increasing access to care and clinical trials. Collaborative operations will launch in early 2026, featuring a focus on new facilities with latest medical technology.
Groundbreaking research from the CLEAR study reveals that greater tumor shrinkage improves survival outcomes for patients with advanced renal cell carcinoma. The lenvatinib and pembrolizumab combination regimen demonstrates significant long-term benefits, including enhanced effectiveness of subsequent treatments.
The joint venture will unite the nation's largest comprehensive pediatric system with a top pediatric cancer program and the nation's leading comprehensive cancer center. The collaboration aims to accelerate improved outcomes for patients in Texas and around the world, increasing access to clinical trials and innovative treatments.
Researchers found that a combination of Panitumumab and low-dose Capecitabine is an effective and well-tolerated maintenance regimen for patients with wild-type KRAS metastatic colorectal cancer. The treatment delayed disease progression while managing side effects, improving patients' quality of life.
A study found racial and ethnic minorities are less likely to receive standard-of-care diagnostic imaging after abnormal screening mammograms compared to white patients. Minority groups were also less likely to have access to same-day biopsy services, despite similar availability of most diagnostic services.
Researchers at Aston University and the Royal Orthopaedic Hospital are developing an injectable paste using gallium-doped bioglass to treat bone cancer. The substance has anticancer and bone regenerative properties, showing a 99% success rate in eliminating cancerous cells.
Amplified Sciences has received CLIA certification for its PanCystPro test, which helps risk stratify patients with pancreatic cystic lesions. The company plans to commercialize the test through an early access program and a clinical utility trial in 2025.
ABT-263 eliminates harmful aging cells in the gut, reducing inflammation and lowering cancer risk in a mouse model of GI cancer. The study suggests that removing senescent cells could help prevent radiation-related GI cancer, highlighting the potential of senolytic drugs as a preventive treatment.
Researchers found that Black women with triple-negative breast cancer are less likely to receive immunotherapy treatment, even when accounting for socioeconomic factors. The study analyzed data from over 10,000 patients and found a significant disparity in immunotherapy response between racial groups.
Researchers have developed a 'gut-on-chip' model that replicates intestinal inflammation and predicts response to immunotherapy in melanoma patients. The device differentiates between major intestinal populations and reproduces realistic environments.
A study found that 77.9% of lung cancer patients had detectable atherosclerosis on CT scans, with smoking being the most prominent cardiac risk factor. The results suggest using concurrent coronary calcium scoring to aid in identification and earlier intervention for these patients.
Researchers found that flagellin from the gut disrupts immune checkpoint treatment in ovarian cancer patients. Inhibiting this pathway may enhance clinical outcomes and save lives. The discovery could lead to novel therapies capable of targeting ovarian tumors.
A preclinical study reveals that tumors drive clot formation by releasing chemokines, prompting immune cells to release small vesicles that attach to cell fragments, forming life-threatening clots. The findings may lead to diagnostic tests and safer therapies to target the root of blood clotting risk.
New cyanine-carborane salts show promise in eradicating metastatic breast cancer tumors with minimal side effects. The therapy targets specific proteins in cancer cells, allowing for precise killing of diseased cells while sparing healthy tissue.
Researchers at Osaka Metropolitan University assessed target genes in canine hepatocellular carcinoma (HCC) to develop molecular targeted therapies. The study identified potential gene targets, including PDGFB, which may improve treatment options for unresectable HCC.
The National Foundation for Cancer Research (NFCR) has launched a new podcast called All Things Cancer. The podcast is hosted by Sujuan Ba, Ph.D., and features conversations with leading scientists, oncologists, doctors, patient advocates, caregivers, biotech innovators, and survivors.
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
A new study reveals that microglia can be reprogrammed from a tumor-promoting state to one that strengthens antitumor responses, reducing brain metastases growth and enhancing immunotherapy responses. Researchers identified a key signaling pathway that, when blocked, reverses the protumoral function of microglia.
A multicenter study found that electronic symptom monitoring improved quality of life, clinical outcomes, and well-being in metastatic cancer patients. The PRO-TECT trial showed significant benefits for patients who reported their symptoms via a home-based electronic monitoring system.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
A new 3D bioprinted gastric cancer model successfully replicates the unique characteristics of individual patients' tissues, predicting drug responses and prognosis with high accuracy. This innovative platform enables rapid evaluation within two weeks, contributing to personalized cancer treatment development.
Researchers identified a method to enhance CAR-T cell therapy by modifying the CUL5 gene. This approach improves T cells' growth and longevity, making them more effective in fighting cancer. The study suggests a new way to create targeted cells using a virus to deliver genetic material.
A new genetic mutation, RUFY1-RET fusion, was discovered in a patient with stage IV CD-74-ROS1 fusion NSCLC who developed resistance to lorlatinib. The finding highlights the importance of ongoing genetic testing to guide therapy decisions.
A Virginia Tech research team has made significant progress in understanding the role of physical properties in tuning the body's immune responses. By modifying biomaterials' size, shape, and stiffness, they aim to enhance immune cell behavior and stimulate antitumor immune responses.
The ACC Advancing the Cardiovascular Care of the Oncology Patient conference will provide clinicians with tools to improve cardiovascular care of cancer patients. Key sessions will include discussions on pulmonary tumor thrombotic microangiopathy, AI and technology in cardio-oncology.
A phase 1 trial of a personalized cancer vaccine for patients with stage III or IV clear cell renal cell carcinoma showed a positive response in all nine patients, with no higher-grade side effects reported. The vaccine generated a successful anti-cancer immune response and kept patients cancer-free at the time of data cut-off.
A new study found that RAD51 testing can complement next-generation sequencing in personalizing prostate cancer treatment, especially for patients with homologous recombination repair-defective tumors. The biomarker showed high sensitivity and specificity for identifying BRCA1/2 alterations.
The National Comprehensive Cancer Network is joining the global effort to improve awareness and knowledge of cancer risks through its 'United by Unique' campaign. Patient advocates from NCCN guidelines panels are sharing their personal stories to highlight the importance of a people-centered approach in cancer care, which recognizes ev...
Researchers at the CNIC have designed a treatment strategy to protect the heart against cardiotoxic effects of anthracyclines, a common class of anticancer drugs. Empagliflozin, an SGLT2 inhibitor, has been shown to preserve cardiac function and metabolism in experimental models.
The Neuro-Oncology Translational Research Training Program aims to bridge laboratory discoveries and clinical applications in neuro-oncology, targeting glioblastoma and brain metastases. The program provides predoctoral and postdoctoral trainees with cutting-edge lab experience and mentorship across multiple disciplines.
A new Phase I clinical trial from London Health Sciences Centre Research Institute found high-precision radiation therapy to be safe in treating patients with polymetastatic disease. The study, known as ARREST, used stereotactic ablative radiotherapy (SABR) to treat cancer that has spread to more than 10 spots in the body.
Researchers created a new biologic compound using protein engineering to maximize therapeutic effects while reducing toxicity. The modified enzyme effectively destroyed leukemia cells in mice without common side effects, shrinking tumors in additional cancer models.
A recent study published in Lancet Oncology reveals a significant link between early side effects from radiation therapy for prostate cancer and long-term complications. Men who experience moderate acute urinary or bowel side effects during treatment are nearly twice as likely to develop late urinary or bowel issues, respectively. This...
The addition of da Vinci 5 robotic surgical systems at Huntsman Cancer Institute offers enhanced precision and control during minimally invasive surgeries. The system's advanced technology enables complex procedures to be performed through small incisions, reducing hospital stays and accelerating recovery times for patients.
Researchers at Memorial Sloan Kettering Cancer Center have made a breakthrough in creating allogeneic CAR T cells that can persist in fighting cancer without being rejected by patients. By modifying donor cells with the HIV protein Nef, the cells can survive and remain potent in treating various types of cancer.
A phase 2 clinical trial found that a combination of two HER2 inhibitors was more effective and better tolerated than standard EGFR inhibitor-based therapy for patients with HER2-positive metastatic colorectal cancer. The study showed that the level of HER2 amplification in tumors played a key role in determining treatment outcomes.
Researchers at the University of Pittsburgh have developed a new way to grow T cells that can live longer and better destroy cancer cells in mice. By adding a compound called dichloroacetate to growth media, they created T cells less reliant on glucose and more efficient at using other energy sources.
A pooled data analysis found that cancer chemotherapy is linked to persistent severe peripheral nerve pain for around 4 in every 10 patients, with platinum-based drugs and taxanes associated with the highest rates of painful neuropathy. The study analyzed data from 77 eligible studies involving 10,962 participants from 28 countries.
Researchers tracked cfDNA levels before, during, and after colorectal cancer surgery, revealing significant increases associated with age, comorbidities, and surgical manipulation. The study suggests that cfDNA could serve as a non-invasive biomarker to monitor patient outcomes and evaluate surgical effectiveness.
Research presented at the 2025 STS Annual Meeting reveals that anatomic lung resections such as lobectomy and segmentectomy are associated with improved long-term survival compared to wedge resection for stage 1A NSCLC. Lobectomy offered the highest survival rates, with a 71.9% 5-year OS and 44.8% 10-year OS.
Patients with BRAF V600E mutations showed a 60.9% overall response rate to a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy, compared to 40% with standard-of-care treatment. This triple-combination therapy offers an effective new first-line treatment option for patients with this mutation.
A blood test detecting circulating tumor DNA (ctDNA) can predict stage 3 colon cancer patients' risk of recurrence. Adding anti-inflammatory drug celecoxib to post-surgery treatment improves disease-free survival for those with positive ctDNA tests.
The Varian Ethos 2.0 system enables precise and adaptive radiation therapy for multiple types of cancer, including prostate, lung, breast, and others. This technology allows for personalized treatment plans to be updated daily to match the changing anatomy of the patient.
Researchers found that pomalidomide enhances key immune cells, such as T cells and natural killer cells, which helps the body recognize and destroy cancer cells. This leads to improved immune profiles in patients with myeloma, resulting in longer progression-free survival periods.
A University of Minnesota Medical School study reveals that medical equipment is the leading cause of out-of-pocket costs for cancer patients, with wheelchairs and hearing aids among the most expensive items. The research emphasizes the need to address accessibility and affordability issues to improve cancer survivor care.
The RSClin Tool N+ provides more accurate estimates of recurrence risk and individual chemotherapy benefit in node-positive breast cancer. The tool combines clinical and pathologic factors with the 21-gene Oncotype DX Breast Recurrence Score to predict patient-level prognosis and treatment benefit.